Liposome Technologies 

Liposome Design, Optimization and Characterization Services

Liposome-based formulations are becoming more popular because of their unique benefits, such as solubility manipulation of small organic molecules, protecting the embedded molecules from degradation, and site-specific delivery.  Each of these benefits is extremely important for efficient formulations.  The caveat of liposome-based formulation is that the preformulation exercise is time consuming and thus liposomes are usually considered at the later stage of drug development.

Our focus is on inventing and developing all aspects of liposome related technologies with two main goals;
·        accelerating the preformulation optimization, and
·        evaluating the benefits of liposomes at an early stage of R&D. 
Efficient, novel liposome technology allows the liposome-based approach to develop a wide parameter range screening system for preformulation exercises and study the solubility of pharmaceutically relevant compounds at the chemical library level.  Consequently, there is a possibility to identify new formulations and valuable leads or drug candidates, which were missed or overlooked by previous technologies.
There are three areas of our service that makes our organization unique and differentiate us from other liposome producing organizations. 
·        One is our work on developing new and proprietary tools for parallel liposome production and parallel liposome filling to increase the throughput and efficiency of liposome preformulation development. 
·        The second is our extensive experience in analytical and assay development for small organic compounds, polymers, proteins and particles.  The strong analytical background is a key factor for all liposome optimization studies.
·        The third is that we can offer an exclusive immune toxicological evaluation of our liposomes and liposome-based preformulation and formulation products. 
One of the tools we are developing is intended to increase the extrusion throughput for liposome production.  The current technology uses an extrusion system, where the generation of liposomes at a required size, is done in batch mode in a sequence.  We are working on a parallel extrusion technology that permit the production of liposomes built from various lipid compositions at the same time.  This proprietary technology allows us to make small experimental batches of chemically different liposomes in a time efficient way. 




The most significant bottleneck in liposome-based formulation development is the optimization of the filling of the liposomes with the drug of interest. Our technologies allow us to perform parallel liposome filling. The parallel technology also permits systematic parameter optimization. Obviously, the increased throughput also increases the efficiency of preformulation and formulation research.


The increased throughput allows us to be involved at an early stage of drug development, study the solubility of small focused chemical libraries and find previously missed or ignored potentially valuable lead compounds. 
Since liposome formulations are not necessarily applicable directly for the existing high throughput (HT) assays. We offer to develop or modify some of the existing enzyme-based HT assays for liposome formulation. 


Our experience with analytical method developments for both pharmaceutical and biopharmaceutical products has crucial importance in any project.  We can develop and conveniently implement the necessary analytical support for our liposome-based work.  We have strong liposome characterization capabilities as well as competence for measuring and optimizing embedding efficiency.
The combination of parallel liposome preparation and parallel liposome filling should significantly increase the opportunity to develop proprietary and patentable liposome formulations.
An often occurring immune reaction to liposome formulation could be related to aggregation of liposomes. We developed extensive experience on liposome aggregation and the effect of aggregation in vitro and in-vivo systems.


A major risk with any drug formulation is the possibility to induce the immune system of patients occasionally creating a deadly immune response.  Unfortunately there is only one method that can predict immune toxicological response.  We can offer this unique service containing a set of in vitro and in vivo immune toxicological studies, for various drug formulations, including proteins as well.